PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Cost reduction while TRVN shows 765.14% growth. Joel Greenblatt would examine competitive advantage.
41.00%
Positive growth while TRVN shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-31.86%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-15.50%
G&A reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.75%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-27.36%
Total costs reduction while TRVN shows 11.76% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
D&A reduction while TRVN shows 177.38% growth. Joel Greenblatt would examine efficiency.
28.32%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
27.93%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.21%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
29.77%
Pre-tax income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
128.31%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
29.77%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
30.61%
EPS growth while TRVN declines. John Neff would investigate advantages.
30.61%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
2.13%
Share count reduction exceeding 1.5x TRVN's 12.07%. David Dodd would verify capital allocation.
2.13%
Diluted share reduction exceeding 1.5x TRVN's 12.07%. David Dodd would verify capital allocation.